Literature DB >> 12655058

Pitx3 is required for development of substantia nigra dopaminergic neurons.

Irene Nunes1, Lucy T Tovmasian, Robert M Silva, Robert E Burke, Stephen P Goff.   

Abstract

Dopaminergic (DA) neurons of substantia nigra in the midbrain control voluntary movement, and their degeneration is the cause of Parkinson's disease. The complete set of genes required to specifically determine the development of midbrain DA subgroups is not known yet. We report here that mice lacking the bicoid-related homeoprotein Pitx3 fail to develop DA neurons of the substantia nigra. Other mesencephalic DA neurons of the ventral tegmental area and retrorubral field are unaltered in their dopamine expression and histological organization. These data suggest that Pitx3-dependent gene expression is specifically required for the differentiation of DA progenitors within the mesencephalic DA system.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12655058      PMCID： PMC153078          DOI： 10.1073/pnas.0230529100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  22 in total

1.  Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice.

Authors:  A Wallén; R H Zetterström; L Solomin; M Arvidsson; L Olson; T Perlmann
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

Review 2.  Cell therapy in Parkinson's disease - stop or go?

Authors:  S B Dunnett; A Björklund; O Lindvall
Journal:  Nat Rev Neurosci       Date:  2001-05       Impact factor: 34.870

Review 3.  The bicoid-related Pitx gene family in development.

Authors:  P J Gage; H Suh; S A Camper
Journal:  Mamm Genome       Date:  1999-02       Impact factor: 2.957

4.  A double-deletion mutation in the Pitx3 gene causes arrested lens development in aphakia mice.

Authors:  D K Rieger; E Reichenberger; W McLean; A Sidow; B R Olsen
Journal:  Genomics       Date:  2001-02-15       Impact factor: 5.736

5.  Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice.

Authors:  W Le; O M Conneely; L Zou; Y He; O Saucedo-Cardenas; J Jankovic; D R Mosier; S H Appel
Journal:  Exp Neurol       Date:  1999-10       Impact factor: 5.330

6.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Authors:  P Damier; E C Hirsch; Y Agid; A M Graybiel
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

Review 7.  Reward signaling by dopamine neurons.

Authors:  W Schultz
Journal:  Neuroscientist       Date:  2001-08       Impact factor: 7.519

8.  Nigrostriatal innervation is preserved in Nurr1-null mice, although dopaminergic neuron precursors are arrested from terminal differentiation.

Authors:  J Witta; J S Baffi; M Palkovits; E Mezey; S O Castillo; V M Nikodem
Journal:  Brain Res Mol Brain Res       Date:  2000-12-08

9.  A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b.

Authors:  M P Smidt; C H Asbreuk; J J Cox; H Chen; R L Johnson; J P Burbach
Journal:  Nat Neurosci       Date:  2000-04       Impact factor: 24.884

10.  Deletion in the promoter region and altered expression of Pitx3 homeobox gene in aphakia mice.

Authors:  E V Semina; J C Murray; R Reiter; R F Hrstka; J Graw
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150
View more
  119 in total

Review 1.  Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms.

Authors:  Brigitte Malgrange; Laurence Borgs; Benjamin Grobarczyk; Audrey Purnelle; Patricia Ernst; Gustave Moonen; Laurent Nguyen
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

2.  Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a.

Authors:  Gonçalo Castelo-Branco; Joseph Wagner; Francisco J Rodriguez; Julianna Kele; Kyle Sousa; Nina Rawal; Hilda Amalia Pasolli; Elaine Fuchs; Jan Kitajewski; Ernest Arenas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

3.  SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells.

Authors:  Julianna Kele; Emma R Andersson; J Carlos Villaescusa; Lukas Cajanek; Clare L Parish; Sonia Bonilla; Enrique M Toledo; Vitezslav Bryja; Jeffrey S Rubin; Akihiko Shimono; Ernest Arenas
Journal:  Stem Cells       Date:  2012-05       Impact factor: 6.277

Review 4.  Functions of noncoding RNAs in neural development and neurological diseases.

Authors:  Shan Bian; Tao Sun
Journal:  Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.590

5.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

6.  L-dopa reverses behavioral deficits in the Pitx3 mouse fetus.

Authors:  Gale A Kleven; Heather M Booth; Marco Voogd; April E Ronca
Journal:  Behav Neurosci       Date:  2014-08-25       Impact factor: 1.912

7.  Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.

Authors:  Jisook Moon; Hyun-Seob Lee; Jun Mo Kang; Junpil Park; Amanda Leung; Sunghoi Hong; Sangmi Chung; Kwang-Soo Kim
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

8.  A MicroRNA feedback circuit in midbrain dopamine neurons.

Authors:  Jongpil Kim; Keiichi Inoue; Jennifer Ishii; William B Vanti; Sergey V Voronov; Elizabeth Murchison; Gregory Hannon; Asa Abeliovich
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

Review 9.  Induced neuronal reprogramming.

Authors:  Cheen Euong Ang; Marius Wernig
Journal:  J Comp Neurol       Date:  2014-05-21       Impact factor: 3.215

10.  Nato3 integrates with the Shh-Foxa2 transcriptional network regulating the differentiation of midbrain dopaminergic neurons.

Authors:  Einat Nissim-Eliraz; Sophie Zisman; Omri Schatz; Nissim Ben-Arie
Journal:  J Mol Neurosci       Date:  2012-12-21       Impact factor: 3.444
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.